Sartorius/€SRT3

06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX

About Sartorius

Sartorius AG, trading under the ticker symbol SRT3, is a global provider of laboratory and bioprocess technologies, offering products and services that cater to the needs of the biopharmaceutical and research industries. Founded in 1870 and headquartered in Göttingen, Germany, the company specializes in filtration, fermentation, fluid management, and laboratory products, supporting clients ranging from research facilities to large-scale biopharmaceutical manufacturers. Operating internationally, Sartorius is crucial in enabling the development and production of biotech medications and vaccines, solidifying its role as a crucial player in the life sciences and biotechnology sectors.

Ticker

€SRT3
Sector
Health

Primary listing

XETRA

Employees

13,878
Headquarters
Göttingen, Germany
Website
www.sartorius.com

Sartorius Metrics

BasicAdvanced
€14B
-
-
-
€0.74
0.33%

What the Analysts think about Sartorius

Analyst ratings (Buy, Hold, Sell) for Sartorius stock.

Bulls say / Bears say

Group sales revenue rose 7.5% in the first nine months of 2025 with underlying EBITDA increasing by around 13%, boosting the EBITDA margin to 29.7% and prompting management to sharpen full-year guidance to approximately 7% growth and a margin slightly above 29.5% (Sartorius).
In H1 2025, the Bioprocess Solutions division grew sales by 8.8% in constant currencies to €1.435 billion, driving underlying EBITDA up 16.5% and expanding the margin to 31.6% on strong consumables demand (Sartorius).
The July 2025 acquisition of microtissue specialist MATTEK contributed nearly 1 percentage point to the Lab Products & Services division’s sales growth, diversifying Sartorius’s portfolio into high-growth microtissue technologies (Sartorius).
The Lab Products & Services division saw sales revenue decline by 3.2% to €495 million in the first nine months of 2025, with underlying EBITDA falling to €108 million and margins contracting to 21.7%, underscoring persistent weakness in lab instrument demand (Sartorius).
Industry-wide reluctance to invest has kept the bioprocess equipment and systems business soft, limiting higher-margin growth potential and leaving Sartorius heavily reliant on consumables for profitability (Sartorius).
Management’s guidance for full-year 2025 includes caveats around existing tariffs that could temporarily depress sales growth and margin expansion, reflecting uncertainty in cost structures and pricing power (Sartorius).
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2025.

Sartorius Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Sartorius Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €SRT3

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs